EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and TRM cell responses

Zhaojia Wu, Zhenyu Yang, Tauqeer Iftikhar, Gary Groot, Scot C Leary, Nicolas Baniak, Shahid Ahmed, Mark Bosch, Michael Moser, Wenjun Zhang, Junhong Jiang, Jim Xiang

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04217-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Zhaojia Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Saskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK, Canada. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Electroporation, CD40 Antigens, Dendritic Cells. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Innovation Research Project of Medical and Health Care of Suzhou, the Science and Technology Project of Suzhou Municipal Health Commission, the Cancer Research Society Charlotte Legare Memorial Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Melanoma is one of the deadliest forms of skin cancer. Irreversible electroporation (IRE) is an innovative, non-thermal ablation technology for treating irresectable solid cancers. However, most IRE treatments are incapable of cancer eradication and only temporarily prolong patient survival. METHODS: In this study, we developed a novel IRE + Combo treatment regimen that combines IRE-ablation with Combo-adjuvant [CpG, anti-PD-L1 antibody (PD-L1-Ab) and CD40-agonist] and investigated its anti-tumor immunity in a mouse BL6-10OVA (BLOVA) melanoma model. RESULTS: We demonstrated that inclusion of the CD40-agonist in the IRE + Combo treatment regimen promoted a more robust CD8+ T cell response (6.89%) when compared with IRE + CpG/PD-L1-Ab (2.67%) or IRE alone (0.21%) treatments, leading to eradication of subcutaneous BLOVA melanoma in 5/8 of BLOVA-bearing mice and simultaneous elimination of lung melanoma metastases. Addition of CD40-agonist to the IRE + Combo treatment regimen also induced a higher frequency (17.1%) of CD8+CD103+ conventional type-1 dendritic cells (cDC1s) with up-regulated expression of CD54, CD80, MHC II, Bcl-xL and 41BBL in tumor-drainage lymph nodes (TDLNs) relative to the control IRE + CpG/PD-L1-Ab (12.1%) and IRE alone (9.0%) treatment groups. We also show that CD40-agonist stimulated a higher frequency of CD103+TCF1+ tissue-resident memory T (TRM) cells (32.1%) in TDLNs when compared with the two control (15.3% and 6.7%) treatment groups, and that these TRM cells exhibited enhanced mitochondrial content and greater relative expression of the effector cytokines IFN-γ and TNF-α and the transcriptional regulators TRAF1, p38-MAPK and PGC-1α. CONCLUSION: Taken together, this study establishes that the CD40-agonist greatly potentiates the efficacy of IRE-ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and CD103+TCF1+ TRM cell responses and suggests the importance of targeting CD40-signaling to improve the efficacy of cancer IRE-ablation therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesElectroporationCD40 AntigensDendritic CellsSkin NeoplasmsMelanomaMelanoma, ExperimentalAnimalsMiceIntegrin alpha ChainsAntigens, CDMice, Inbred C57BLFemaleCell Line, TumorHumans

Stichwörter der Autor:innen

CD103+ TRM cellCD40-agonistCD8+CD103+ cDC1IRE-ablationMetastatic melanomaPD-1 blockade

Substanzen

CD40 Antigensalpha E integrinsIntegrin alpha ChainsAntigens, CD

Autor:innen und Institutionen

  • Saskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
  • Department of Oncology, University of Saskatchewan, Saskatoon, SK, Canada.
  • Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Surgery, University of Saskatchewan, Saskatoon, SK, Canada.
  • Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, SK, Canada.
  • Department of Pathology, University of Saskatchewan, Saskatoon, SK, Canada.

Förderung

  • The Innovation Research Project of Medical and Health Care of Suzhou
  • the Science and Technology Project of Suzhou Municipal Health Commission
  • the Cancer Research Society Charlotte Legare Memorial Fund
  • CoMRAD grant from the College of Medicine, University of Saskatchewan
  • Saskatchewan Cancer Agency Operating Grant with funds donated to the Cancer Foundation of Saskatchewan

Zitieren

APA

Wu, Z., Yang, Z., Iftikhar, T., Groot, G., Leary, S. C., Baniak, N., Ahmed, S., Bosch, M., Moser, M., Zhang, W., Jiang, J., & Xiang, J. (2025). CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and TRM cell responses. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04217-7

Vancouver

Wu Z, Yang Z, Iftikhar T, Groot G, Leary SC, Baniak N, et al. CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and TRM cell responses. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04217-7

BibTeX
@article{Wu2025,
  author = {Wu, Zhaojia and Yang, Zhenyu and Iftikhar, Tauqeer and Groot, Gary and Leary, Scot C and Baniak, Nicolas and Ahmed, Shahid and Bosch, Mark and Moser, Michael and Zhang, Wenjun and Jiang, Junhong and Xiang, Jim},
  title = {CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and TRM cell responses},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04217-7}
}
Kostenlos starten →